Stock Fundamentals

Company Information

Company Name
Ventyx Biosciences Inc
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
ISIN: US92332V1070
CIK: 0001851194
CUSIP: 92332V107
Currency: USD
Full Time Employees: 83
Phone: 760-407-6511
Fiscal Year End: December
IPO Date: Oct 21, 2021
Description:

Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases. Its pipeline includes small molecule therapeutics to treat inflammation across cardiometabolic disorders, neurodegenerative diseases, and inflammatory disorders. The company's portfolio of NLRP3 inhibitors includes VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for Crohn's disease. It is also developing Tamuzimod, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor that is in a Phase 2a trial for patients with early Parkinson's disease and is in a Phase 2 trial for patients with obesity and additional risk factors for cardiovascular disease. Ventyx Biosciences, Inc. was incorporated in 2018 and is headquartered in San Diego, California. As of March 4, 2026, Ventyx Biosciences, Inc. operates as a subsidiary of Eli Lilly and Company.

Address:

12790 El Camino Real, San Diego, CA, United States, 92130

Directors & Officers

Name Title Year Born
Dr. Sheila K. Gujrathi M.D. Executive Chairperson 1970
Ms. Snehal Naik Ph.D. Senior Vice President of Clinical Development NA
Ms. Kathy Ogilvie Ph.D. Senior Vice President of Translational & Nonclinical Research NA
Ms. Arline Nakanishi Senior Vice President of Biometrics NA

Insider Trading

Date Insider Name Title Transaction Type Shares Price Value
Dec 18, 2025 John Nuss N/A Sale 12.68K $7.72 $97.85K
Dec 18, 2025 Raju Mohan N/A Sale 47.35K $7.72 $365.50K

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
Affinity Asset Advisors, LLC 6.48M Dec 31, 2025 9.04% $3.34 65.24%
Vanguard Group Inc 3.94M Dec 31, 2025 5.50% $0.00 4.60%
TANG CAPITAL MANAGEMENT LLC 2.81M Dec 31, 2025 3.92% $1.26 -9.23%
Baker Bros Advisors LP 2.35M Dec 31, 2025 3.27% $0.12 129.62%
BRAIDWELL LP 1.92M Dec 31, 2025 2.68% $0.55 0.00%
D. E. Shaw & Co LP 1.67M Dec 31, 2025 2.32% $0.01 218.64%
MPM Oncology Impact Management LP 1.64M Dec 31, 2025 2.28% $1.69 0.00%
Citadel Advisors Llc 1.56M Dec 31, 2025 2.18% $0.00 -16.83%
JPMorgan Chase & Co 1.50M Sep 30, 2025 2.08% $0.00 226.73%
Connor Clark & Lunn Inv Mgmt Ltd 1.20M Dec 31, 2025 1.68% $0.03 13.60%
BlackRock Inc 1.18M Sep 30, 2025 1.65% $0.00 -13.51%
Susquehanna International Group, LLP 1.12M Dec 31, 2025 1.56% $0.00 64.46%
Point72 Asset Management, L.P. 1.06M Dec 31, 2025 1.47% $0.01 -67.08%
683 Capital Management LLC 1.04M Dec 31, 2025 1.45% $0.41 4.00%
Millennium Management LLC 989.92K Dec 31, 2025 1.38% $0.00 -40.07%
Ikarian Capital, LLC 958.70K Dec 31, 2025 1.34% $0.68 -26.79%
Jane Street Group LLC 941.07K Dec 31, 2025 1.31% $0.00 144.37%
The Goldman Sachs Group Inc 837.60K Dec 31, 2025 1.17% $0.00 105.84%
Dimensional Fund Advisors, Inc. 742.54K Dec 31, 2025 1.03% $0.00 76.23%
Balyasny Asset Management LLC 735.71K Dec 31, 2025 1.03% $0.01 0.00%

Shares Statistics

Shares Outstanding: 71.75M
Shares Float: 47.85M
% Insiders: 421.80%
% Institutions: 8,449.80%
Short % Float: 6.93%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 Vanguard Total Stock Mkt Idx Inv 2.01M 2.81% ▲ 0.00% Feb 28, 2026
2 BlackRock Event Driven Equity Instl 1.03M 1.44% ▲ 0.00% Feb 28, 2026
3 Vanguard Institutional Extnd Mkt Idx Tr 699.62K 0.97% ▲ 0.31% Feb 28, 2026
4 BlackRock Health Sciences Opps Inv A 590.65K 0.82% ▼ 0.74% Feb 28, 2026
5 Arbitrage R 575.00K 0.80% ▲ 0.00% Feb 28, 2026
6 Nomura Healthcare Fund Class I 430.00K 0.60% ▲ 0.00% Feb 28, 2026
7 Vanguard Strategic Equity Inv 409.36K 0.57% ▲ 43.35% Dec 31, 2025
8 Fidelity Extended Market Index 334.85K 0.47% ▼ 0.36% Feb 28, 2026
9 GAMCO Intl SICAV Merger Arbtrg I (USD) 313.48K 0.44% ▲ 0.00% Feb 28, 2026
10 BlackRock Health Sciences Term Trust 222.62K 0.31% ▲ 0.00% Dec 31, 2025

Valuation Metrics

Enterprise Value: $821.89M
Trailing P/E: 0.00
Forward P/E: 0.00

Financial Highlights

Market Cap: $1.00B
EBITDA: $-116.44M
Book Value: $2.68
Earnings/Share: $-1.49
Profit Margin: 0.00%
Operating Margin: 0.00%
ROA (TTM): -28.47%
ROE (TTM): -45.35%
Revenue (TTM): $0.00
Revenue/Share (TTM): $0.00
Earnings Growth (YOY): 0.00%
Revenue Growth (YOY): 0.00%

Stock Price History

1 Year Price History

2 Years Price History

5 Years Price History

10 Years Price History

Financial Charts

Revenue & Net Income (Yearly)

Revenue & Net Income (Quarterly)

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Yearly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Earnings Per Share (EPS) History

Financial Ratios

Balance Sheet (Yearly)

Financial Ratios

Date Current Ratio Debt/Equity Debt/Assets Interest Coverage Debt/EBITDA
2024-12-31 17.97x 0.00x 0.08x N/A -0.01x
2023-12-31 11.87x 0.00x 0.12x N/A 0.00x
2022-12-31 20.21x 0.00x 0.05x -24.02x 0.00x
2021-12-31 21.41x 0.00x 0.04x -678.25x 0.00x
2020-12-31 0.17x -0.41x 126.12x -19.69x -1.79x
2019-12-31 0.55x -0.93x 12.83x -28.63x -3,846.00x

📦 Raw API Data (JSON Explorer)

Watchlist

0

No stocks in watchlist

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about VTYX.US!